Almost everything written about AAS bloodwork is written for men. The reference ranges, the risk profiles, the monitoring schedules: they all assume a male endocrine system. Female physiology is not "male physiology with lower testosterone." It is fundamentally different in ways that matter for every single marker panel.
Women produce estrogen and progesterone in cyclic patterns that influence liver proteins, iron metabolism, thyroid function, and lipid profiles. AAS interact with all of these systems, and the interaction is different than what happens in men. The result: a low HDL reading or a suppressed TSH might mean something entirely different for a female athlete.
This guide covers the six areas where female-specific bloodwork interpretation matters most: from cycle timing to iron management to thyroid monitoring. You'll get actionable data from every blood draw, not numbers that look abnormal because they are being judged against male-derived reference ranges.
Hormonal Baseline: What 'Normal' Means for Women
The female endocrine system operates on a roughly 28-day cycle driven by estrogen and progesterone. This is not a trivial detail. These hormones directly affect your blood work. Estrogen stimulates SHBG production in the liver, increases cortisol-binding globulin, and influences thyroid-binding globulin. When you introduce exogenous androgens, you disrupt this entire regulatory system.
Women naturally have higher SHBG than men because estrogen upregulates hepatic SHBG synthesis, so a given dose of AAS has different free-androgen dynamics in women. More of the compound gets bound, which can both reduce efficacy and alter the side effect profile, and when AAS suppress SHBG, which they do universally, the effect is more pronounced because you start from a higher baseline.
Endogenous hormone production differs as well. Women produce small amounts of testosterone, about 15 to 70 ng/dL, plus androstenedione from the ovaries and adrenal glands. Add exogenous AAS and endogenous production shuts down, but the clinical consequences of suppression are less immediately apparent than in men. There's no dramatic drop in libido or erectile function to signal the need for blood work.
SHBG: The Female Amplifier
Menstrual Cycle and Bloodwork Timing
The single most underappreciated variable in female blood work is cycle timing. Your menstrual phase at the time of the draw can shift values by 10-20% for several critical markers. Ignoring this makes your results essentially uninterpretable: you are comparing a luteal-phase blood panel to follicular-phase reference ranges and wondering why things look off.
What you see on your bloodwork depends heavily on where you are in the cycle. Timing changes everything.
Follicular Phase vs. Luteal Phase: Marker Differences
| Marker | Follicular (Days 1–14) | Luteal (Days 14–28) |
|---|---|---|
| TSH | Lower, more stable — reliable baseline | 10–20% higher — progesterone drives TSH up |
| Free T4/T3 | Stable reference values | May appear falsely low due to TBG shifts |
| Iron / Ferritin | Higher — iron stores are repleting | Lower — menstrual loss + hemodilution |
| Cortisol | Lower baseline — less stress response | Elevated — progesterone is a cortisol competitor |
| Fasting Glucose | More stable, lower values | Higher — progesterone induces mild insulin resistance |
| Estradiol (E2) | Rises to peak ~200 pg/mL at ovulation | Elevated but falling — 100–250 pg/mL range |
The practical takeaway: draw in the follicular phase, ideally between days 3 and 10 of your cycle. That window gives you the most consistent, reproducible baseline. If you draw in the luteal phase, note it, and interpret TSH, iron, and glucose knowing they'll naturally be shifted.
📅A TSH measured in the luteal phase can run meaningfully higher than the same person's follicular-phase value — enough to push a normal result toward the subclinical hypothyroidism range.
Compound Selection and Female-Specific Monitoring
Compound choices for women are more limited than for men, and the monitoring requirements differ. The key principle: androgenicity drives both the desired effects and the risks, and women are more sensitive to androgenic activity at every dose level. A dose that produces mild lipid changes in a man can cause significant virilization in a woman, and the threshold varies between individuals based on genetics, SHBG levels, and androgen receptor sensitivity.
The most commonly used compounds break down as follows, with female-specific dosing and monitoring guidance included for each one.
Female-Specific Compound Comparison
| Marker | Typical Dose Range (Reported) | Profile & Monitoring Notes |
|---|---|---|
| Anavar (oxandrolone) | 5–20 mg/day oral | Most studied compound in women, generally considered to have the mildest side-effect profile among oral AAS in this context. HDL impact is the limiting factor to monitor — if HDL drops below 30 mg/dL, that is a signal to reduce dose or stop, not to push through. |
| Primobolan (methenolone) | 50–150 mg/week injectable | Injectable form avoids liver stress and tends to have a milder lipid impact than oral options. The acetate ester clears faster than enanthate, which matters if side effects need to resolve quickly. |
| Winstrol (stanozolol) | 5–15 mg/day oral | The most androgenic per mg of the compounds listed here. HDL drops of 50–70% are common. Voice changes or clitoral sensitivity are early virilization signs that call for immediate discontinuation — these effects can become permanent with continued exposure. Not recommended for first-time users. |
| Testosterone propionate | 5–15 mg/day (35–105 mg/week) | Short ester allows rapid discontinuation if sides emerge. Used more in experienced female athletes. Monitor free T and SHBG closely. Hair loss and acne are common even at low doses. |
| Nandrolone (Deca) | 25–75 mg/week | Low androgenicity but progestogenic activity can affect mood and libido. Long half-life (15 days for decanoate) means sides persist for weeks after cessation. Nandrolone phenylpropionate (NPP) has a shorter clearance time. |
Key dosing principles for women:
- Start low, go slow: Begin at the lowest effective dose and titrate up over weeks, not days. The androgenic threshold is individual, and crossing it produces side effects that are not always reversible.
- Short esters first: Choose compounds with shorter half-lives (testosterone propionate over enanthate, nandrolone phenylpropionate over decanoate). If virilization signs appear, shorter esters clear faster and the side effect progression stops sooner.
- Single compound cycles: Avoid stacking multiple AAS as a first-time user. A single compound at a moderate dose allows you to isolate effects and identify your individual tolerance before considering more complex protocols.
- Cycle length matters: Female AAS cycles are typically shorter than male cycles (6-8 weeks versus 12-20 weeks). The risk of androgenic side effects increases with cumulative exposure time, not just dose.
The Androgenic Threshold
Free Androgen Index
Regular blood work for female AAS users should include: total testosterone, free testosterone (or calculated free T), SHBG, estradiol, LH, FSH, complete lipid profile (total cholesterol, HDL, LDL, triglycerides, ApoB), liver enzymes (AST, ALT, GGT), ferritin, iron panel, TSH, free T4, free T3, and CBC. This is a broader panel than most male users order, and it should be, because the interactions between AAS, the menstrual cycle, and female endocrinology are more complex.
Voice Changes and Androgenic Monitoring
Voice changes are the most psychologically impactful and least reversible androgenic side effect of AAS use in women. Unlike clitoral enlargement, which may partially regress after compound cessation, or increased body hair, which can be managed cosmetically, voice deepening is permanent once threshold damage occurs. The vocal folds (vocal cords) are androgen-sensitive tissue with high concentrations of androgen receptors. When exposed to supraphysiological androgen levels, they thicken and elongate, and unlike muscle tissue, they do not revert to baseline when the stimulus is removed.
Voice changes are subjective and gradual, so monitoring them is tricky. You generally won't notice your own voice shifting while it's happening; other people catch it first. By the time you feel vocal roughness, hoarseness, or a reduced upper vocal range, the structural changes may already be established. That's why objective monitoring tools are critical.
These are the blood markers that correlate with vocal virilization risk.
- The Free Androgen Index (FAI) is the strongest blood-based predictor you have. A FAI above 10 in women correlates with a marked increase in androgenic side effects, including vocal changes. Tracking FAI monthly lets you see the trajectory before symptoms emerge.
- Free testosterone (calculated or direct): Free T above 10-15 ng/dL in women is a warning zone where vocal changes become more likely. The absolute threshold varies, but the rate of change matters: a rapid rise over 4-6 weeks is more dangerous than a gradual increase over months.
- SHBG: Low SHBG (below 20 nmol/L) frees up more androgen to interact with vocal fold tissue. A dropping SHBG trend, even if free T looks stable, should be taken as a warning signal.
- DHT (dihydrotestosterone): The most potent androgen for vocal fold thickening. If you are using compounds that convert to DHT (testosterone, Anavar) or that are DHT derivatives (Winstrol, Primobolan, Masteron), DHT levels provide specific information about androgenic load on vocal tissue.
DHT (Dihydrotestosterone)
Practical voice monitoring protocol:
- Voice journaling: Record a 30-second voice sample weekly (same phrase, same time of day, same recording device). Play back week-over-week to detect subtle changes. Apps like Vocal Pitch Monitor (available on iOS/Android) provide objective frequency tracking. A drop in habitual speaking pitch of more than 20-30 Hz is a warning sign.
- Symptom checklist: Weekly self-check: Do you clear your throat more often? Does your voice tire faster by the end of the day? Have others commented on your voice? Has your singing range narrowed? Any "yes" warrants investigation.
- Blood work correlation: At the first sign of voice change, check total testosterone, free testosterone, SHBG, DHT, and FAI. If free T has doubled from baseline or FAI has crossed 10, consider dose reduction or compound discontinuation.
- Irreversibility awareness: Voice changes from short-term AAS exposure (4-6 weeks) may partially reverse, but changes from cycles lasting 12+ weeks at androgenic doses are typically permanent. The "safe window" for vocal fold recovery is narrower than you think.
Hoarseness Is Not Normal
Iron and Ferritin: The Female Depletion Risk
Women start with lower iron stores than men, with the average premenopausal woman having ferritin levels of 30 to 60 ng/mL compared to 100 to 300 ng/mL in men. This is a direct consequence of menstrual blood loss, which amounts to approximately 10 to 40 mL of blood per cycle, carrying 1 to 3 mg of iron.
Add AAS to the equation and the iron picture gets even more complex. AAS stimulate erythropoiesis, red blood cell production, which increases iron demand. Your bone marrow needs more iron to build more RBCs. Stack that on top of dietary restriction, common in contest prep, and reduced iron intake. Factor in potential menstrual changes, some women experience suppression of menstruation on AAS while others don't, and ferritin can drop rapidly.
Ferritin
The depletion timeline is faster than most athletes realize. A female athlete with baseline ferritin of 50 ng/mL who starts AAS, trains hard, and restricts calories can drop to below 20 ng/mL within 8 to 12 weeks. Symptoms like fatigue, poor recovery, heavy legs, and brain fog are often attributed to training load or AAS side effects when the real cause is iron depletion.
Blood donation adds another layer of risk. Phlebotomy for hematocrit management removes 200-250 mg of iron per donation. For a woman with already low iron stores, a single donation can push ferritin into single digits. The female AAS user who donates blood should be monitored with ferritin levels every 4-6 weeks, and iron supplementation should be considered if ferritin drops below 30 ng/mL.
Iron Supplementation: Don't Guess
Thyroid and AAS in Women
Thyroid dysfunction runs 5 to 10 times more common in women than in men, and that gap is no accident. Autoimmune thyroid conditions like Hashimoto's and Graves' hit women far more often, and when you layer anabolic-androgenic steroids on top of an already complex female endocrine system, most coaches and clinicians are flying blind. The interaction between AAS, thyroid function, and female endocrinology is poorly understood, full stop.
AAS affect the thyroid at multiple levels. Androgens reduce thyroxine-binding globulin (TBG), which affects measured total T4 and T3 without necessarily altering free hormone levels. This can create the appearance of thyroid dysfunction, with low total T4, normal TSH, and normal free T4, but that's actually a harmless binding-protein shift. It can also unmask subclinical thyroid disease that was previously compensated.
TSH (Thyroid-Stimulating Hormone)
Put TSH, free T4, and free T3 in every baseline and follow-up panel. When TSH creeps above 2.5 mIU/L, add anti-TPO and anti-thyroglobulin antibodies to screen for Hashimoto's. AAS-related TBG suppression can mask Hashimoto's by dropping total T4 while free T4 stays normal, and the antibody tests catch what the standard panel misses.
The Luteal Phase TSH Trap
Lipid Differences: The HDL Gap
Women naturally have higher HDL cholesterol than men, typically 50 to 70 mg/dL versus 40 to 55 mg/dL. This is one of the reasons premenopausal women have lower cardiovascular event rates than age-matched men. Estrogen upregulates ApoA1 production, the primary protein in HDL particles, resulting in more and better-functioning HDL.
When women use AAS, the absolute HDL drop is more dramatic than in men. Not because the compounds are more toxic to lipids in women, but because the starting point is higher. A female athlete whose HDL drops from 65 to 35 mg/dL on Anavar has experienced a 46% reduction. A male athlete dropping from 50 to 35 mg/dL has experienced a 30% reduction. The absolute endpoint, 35 mg/dL, is the same, but the physiological context is different.
Lipid Impact: Women vs. Men on AAS
| Marker | Female Baseline + AAS | Male Baseline + AAS |
|---|---|---|
| HDL baseline | 55–70 mg/dL | 40–55 mg/dL |
| HDL on AAS | 30–45 mg/dL | 25–40 mg/dL |
| Absolute drop | 20–30 mg/dL | 10–20 mg/dL |
| Percentage drop | 35–50% | 20–40% |
| ApoB baseline | 60–90 mg/dL | 70–110 mg/dL |
| ApoB on AAS | 80–130 mg/dL | 90–150 mg/dL |
The key insight: the absolute HDL value on AAS matters more than the percentage drop. An HDL of 35 mg/dL is low regardless of whether you started at 65 or 50. But the faster rate of decline in women is worth monitoring more frequently, with quarterly lipid panels during cycle, not just at the start and end.
ApoB is still the most important advanced lipid marker for women on AAS, just like it is for men. An ApoB below 100 mg/dL with HDL above 30 mg/dL gives you a manageable cardiovascular risk profile. But for women, the ApoB/ApoA1 ratio might be the metric that tells you more, because ApoA1, which estrogen drives, drops more sharply in female AAS users.
Bone Health and Blood Markers
Bone density doesn't just hinge on one input. It's regulated by a complex interplay of estrogen, androgens, mechanical loading, and calcium metabolism. For female athletes, AAS create a genuine double-edged sword. On one hand, the androgens actively promote bone formation, which is a positive effect. On the other, the menstrual suppression that comes with AAS use strips away estrogen's bone-protective influence, and that's a real negative. So you get a push in one direction and a pull in the other, and the net result depends on which force wins out.
The net effect comes down to compound choice, dose, and cycle length. Run a mild compound at a moderate dose, say Anavar 10-15 mg/day, and you may keep menstrual function intact while still getting the anabolic bone benefits. Push higher androgen doses or stack compounds together, and menstruation is far more likely to shut down, which takes away estrogen's contribution to maintaining bone density.
Blood markers to monitor for bone health:
- Calcium: Total and corrected calcium (albumin-adjusted): AAS can alter albumin levels, making corrected calcium more accurate than total calcium alone. Ionized calcium (free, unbound calcium) is even more precise but rarely covered by standard panels.
- Vitamin D (25-OH): Maintain above 50 nmol/L, ideally above 75 nmol/L for athletes. Vitamin D status affects calcium absorption and bone turnover. Female athletes are more likely than male athletes to be vitamin D deficient, especially if training indoors or living at northern latitudes. Supplement with 2,000-4,000 IU/day of vitamin D3 if levels are below 50 nmol/L.
- PTH (Parathyroid Hormone): Elevated PTH suggests calcium or vitamin D insufficiency. PTH can rise when AAS alter calcium metabolism or when calcium intake is low. Sustained PTH elevation is catabolic to bone: it signals your body is pulling calcium from the skeleton to maintain blood calcium levels. If PTH is elevated despite adequate vitamin D and calcium intake, investigate further (calcium absorption issues, renal function, or primary hyperparathyroidism).
- Estradiol: If menstrual suppression occurs, estradiol below 50 pg/mL for extended periods (6+ months) raises bone density concerns. This is a female-specific consideration that male AAS users never have to think about. Estradiol's role in bone health is so significant that the Women's Health Initiative (a landmark study published in JAMA) showed that estrogen therapy reduced hip fracture risk by 34% in postmenopausal women: a dramatic effect that underscores what is at stake when estrogen is suppressed.
- Bone turnover markers (advanced): For athletes with prolonged amenorrhea (12+ months) or a family history of osteoporosis, consider adding bone turnover markers: CTX (C-terminal telopeptide, a bone resorption marker) and P1NP (procollagen type 1 N-terminal propeptide, a bone formation marker). An elevated CTX with normal or low P1NP indicates bone loss exceeding bone formation: a red flag that warrants intervention. These markers are not part of standard panels and must be ordered separately, but they provide the earliest objective evidence of AAS-related bone density changes, years before a DEXA scan would detect them.
Bone Health Risk Profile by Compound Type
| Marker | Compound Type | Bone Impact |
|---|---|---|
| Low androgen (Anavar, Primobolan) | Lowest risk of menstrual suppression at moderate doses. Net bone effect likely neutral to positive due to androgenic anabolic stimulus with preserved estrogen. | Monitor estradiol every 8–12 weeks. Most favorable profile for bone health. |
| Moderate androgen (testosterone, nandrolone) | Moderate risk of menstrual suppression, especially above threshold doses. Androgenic bone formation partially offsets estrogen loss but does not fully replace it. | Check estradiol and menstrual status monthly. If suppressed for 6+ weeks post-cycle, investigate. |
| High androgen (Winstrol, Masteron, Trenbolone) | High risk of menstrual suppression and prolonged amenorrhea. Estrogen drops sharply, and bone resorption may outpace formation. | Limit cycle length to 4–6 weeks. Monitor estradiol at mid-cycle and 2 weeks post-cycle. Consider DEXA scan if cycles exceed 12 cumulative weeks per year. |
Calcium intake becomes more critical during AAS use because the combination of increased bone turnover (from androgens) and potential estrogen suppression (from menstrual disruption) creates higher calcium demand. Female athletes using AAS should aim for 1,200-1,500 mg of total daily calcium from diet and supplementation combined: higher than the general recommendation of 1,000 mg. Dairy, calcium-set tofu, fortified plant milks, and sardines with bones are the most bioavailable sources. Calcium carbonate supplements are adequate if taken with food; calcium citrate is preferable for those on proton pump inhibitors or with reduced stomach acid.
Estradiol (E2) in Women
Menstrual Suppression: When to Act
Pregnancy Planning and AAS Cessation Protocol
AAS are contraindicated during pregnancy, not just because of potential virilization of a female fetus, which is the most commonly cited concern, but because AAS disrupt the entire hormonal cascade required for conception, implantation, and early gestation. Planning a pregnancy while using AAS requires a deliberate, structured cessation and recovery protocol that is fundamentally different from a standard post-cycle plan.
The fertility challenge: AAS suppress the hypothalamic-pituitary-ovarian (HPO) axis, reducing LH and FSH production. Without adequate FSH, follicular development does not occur. Without adequate LH, ovulation does not occur. This creates anovulatory cycles: cycles in which no egg is released: making conception impossible. Unlike men, who produce sperm continuously (and can often restore fertility with HCG or clomiphene), women must restore a complete ovulatory cycle, which depends on intricate timing of FSH, LH, estradiol, and progesterone signaling over 4-6 weeks per cycle.
The recommended cessation timeline:
Discontinue all AAS. This is not a taper. Full cessation is required. Do not switch to a "milder" compound or reduce dose; the HPO axis will not recover until all exogenous androgens are cleared. Continue any non-hormonal supplements (creatine, protein, micronutrients) but discontinue anything with direct hormonal activity. Begin tracking your menstrual cycle immediately with ovulation predictor kits or basal body temperature tracking to establish whether ovulatory function has resumed.
Assuming your cycle has resumed, check LH, FSH, estradiol, and progesterone on day 3 and day 21. Day 3 values confirm that FSH is rising appropriately for follicular recruitment, and day 21 progesterone confirms that ovulation occurred. If progesterone is below 5 ng/mL on day 21, ovulation likely did not occur; keep monitoring. If no menstrual period has returned by 12 weeks post-cessation, that's post-AAS amenorrhea and requires endocrinological evaluation.
Iron stores matter a lot when you're planning a pregnancy. If your ferritin sits below 50 ng/mL, start supplementing with iron bisglycinate at 25-50 mg/day and keep going until you hit the target range. Folate is another non-negotiable. Take it as methylfolate, 400-800 mcg/day, and begin at least 4 weeks before you start trying. Neural tube development kicks off before most women even know they're pregnant, so you want those levels locked in early. Vitamin D should stay above 75 nmol/L; deficiency here is linked to pregnancy complications and impaired fetal development. And don't overlook iodine. You need 150 mcg/day for proper fetal thyroid development, and that becomes even more critical if you've been running compounds that mess with thyroid function.
Before attempting conception, run a complete panel: LH, FSH, estradiol, progesterone, total/free testosterone, SHBG, TSH, free T4, free T3, anti-TPO antibodies, ferritin, iron panel, vitamin D, folate, vitamin B12, calcium, and CBC. Every value should sit within normal female reference ranges. If any marker still falls outside range at 16+ weeks post-cessation, investigate before moving forward. AAS can unmask underlying endocrine conditions like thyroid autoimmunity, PCOS, or hypothalamic amenorrhea, and those need independent management rather than just waiting for things to normalize on their own.
AAS and Pregnancy: Zero Tolerance
Fertility Preservation for Future Family Planning
Putting It Together: The Female AAS Bloodwork Protocol
For female AAS users, the complete monitoring protocol combines everything covered above into a practical schedule:
Get your draw in the early follicular phase, days 3 to 7. The full panel covers CBC, CMP, lipids including ApoB, total and free testosterone, SHBG, estradiol, LH, FSH, ferritin, iron panel, TSH, free T4, free T3, vitamin D, calcium (corrected), and PTH. This comprehensive baseline is your reference for every comparison that follows.
The panel covers liver enzymes (AST, ALT, GGT), lipids (HDL, LDL, TG), ferritin, and a CBC. That mid-cycle check is where you catch compound-specific toxicity before it becomes a problem, and it gives you a clear read on your HDL trajectory so you can act before it slides under 30 mg/dL.
Full mid-cycle panel: repeat all baseline markers. Compare to pre-cycle values. This is the decision point: compounds to continue or adjust. If HDL < 25 mg/dL, ferritin < 20 ng/mL, or ALT/AST > 2x upper limit of normal, consider compound modification.
Run the full panel again and line it up against your pre-cycle baseline to confirm recovery is actually happening. Keep a close eye on HDL recovery, ferritin repletion, and thyroid normalization, those are the markers that lag behind. If they haven't returned to baseline within 4 to 6 weeks, don't just keep waiting, extend the monitoring window and dig into why.